Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 23Carcinoma, Non-Small-Cell Lung 16Ovarian Neoplasms 12Fallopian Tube Neoplasms 11Carcinoma, Hepatocellular 10Urinary Bladder Neoplasms 7Pancreatic Neoplasms 7Melanoma 7Colorectal Neoplasms 7Carcinoma, Renal Cell 7Triple Negative Breast Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Mycosis Fungoides 5Endometrial Neoplasms 5Breast Neoplasms 5Lymphoma, T-Cell, Cutaneous 4Glioblastoma 4Thyroid Neoplasms 3Sezary Syndrome 3Nasopharyngeal Carcinoma 3Multiple Myeloma 3Mouth Neoplasms 3Lymphoma, T-Cell 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Brenner Tumor 3Brain Neoplasms 3

Interventions

tremelimumab 1durvalumab 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Immunoglobulin G 1Disulfides 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Malignant Female Reproductive System Neoplasm × Immunoglobulin G × 1 year × Clear all
NCT04395079 2026-02-09

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

Jonsson Comprehensive Cancer Center

Phase 2 Active not recruiting
9 enrolled

Metastatic Malignant Female Reproductive System Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡